Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805)

The Korean Multiple Myeloma Working Party (KMMWP)

Research output: Contribution to journalArticlepeer-review


Optimal treatments for multiple myeloma (MM) patients with high-risk cytogenetics must be determined, but subgroup features are not well-defined. We used real-world data from the Korean Myeloma Registry (KMR) to analyze the characteristics and clinical outcomes of newly diagnosed MM patients with ≥ 1 high-risk cytogenetic abnormality: Group 1: t(4;14) or t(14;16); Group 2: del(17p); Group 3: t(4;14)/del(17p) or t(14;16)/del(17p). Overall, 347 high-risk patients were identified (males, 48.7%; median age, 63 years). Median progression-free survival (PFS) and overall survival (OS) were 19.0 months (95% CI 17.0–20.0) and 50.0 months (95% CI 37.0–61.0), respectively. PFS (p = 0.047) and OS (p = 0.020) differed significantly between groups. After stratification by transplant eligibility, PFS and OS were significantly poorer in Group 3 among transplant-eligible patients, and even poorer in those with gain(1q). Patients stratified by cytogenetic abnormality and revised International Staging System (R-ISS) had significantly different PFS (p < 0.001) and OS (p = 0.003), with the worst survival in R-ISS III/Group 3 (median OS 21.0 months). Higher number of high-risk cytogenetic abnormalities was a negative prognostic marker for PFS and OS (p < 0.001). Real-world KMR data showed that risk factors for poor prognosis of MM patients included del(17p), R-ISS stage, and number of cytogenetic abnormalities.

Original languageEnglish
Pages (from-to)110-121
Number of pages12
JournalInternational Journal of Hematology
Issue number1
Publication statusPublished - 2022 Jul

Bibliographical note

Funding Information:
Under the direction of the authors, medical writing assistance was provided by Robert A. Furlong PhD and David P. Figgitt PhD, ISMPP CMPP™, Content Ed Net, with funding from Amgen Korea.

Funding Information:
This study was funded by Amgen Korea.

Funding Information:
Kihyun Kim, Jin Seok Kim, Sung-Soo Yoon, Dok Hyun Yoon, Hyeon-Seok Eom, Je-Jung Lee, Hyeon Woo Yim, Misun Park and Chang-Ki Min report consultancy and research funding from Amgen Korea. Hojoon Lee reports employment by Amgen Korea.

Publisher Copyright:
© 2022, Japanese Society of Hematology.

All Science Journal Classification (ASJC) codes

  • Hematology


Dive into the research topics of 'Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805)'. Together they form a unique fingerprint.

Cite this